Xvivo Perfusion ABXVIPF -1.32%91 EV-to-OCF is 41.45 as of Jun. 26, 2026, which is 65% below its 10-year median of 116.77. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 89.6% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Xvivo Perfusion AB's Enterprise Value is $807.68 Mil.
Xvivo Perfusion AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $19.49 Mil. Therefore, Xvivo Perfusion AB's EV-to-OCF for today is 41.45.
The historical rank and industry rank for Xvivo Perfusion AB's EV-to-OCF or its related term are showing as below:
XVIPF'
s EV-to-OCF Range Over the Past 10 Years
Min: -943.17 Med: 116.77 Max: 3532
Current: 42.81
During the past 13 years, the highest EV-to-OCF of Xvivo Perfusion AB was 3532.00. The lowest was -943.17. And the median was 116.77.
XVIPF's EV-to-OCF is ranked worse than 89.6% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 7.595
vs XVIPF: 42.81
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xvivo Perfusion AB (OTCPK:XVIPF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xvivo Perfusion AB's PE Ratio (TTM) for today is calculated as:
Xvivo Perfusion AB's share price for today is $29.0011.
Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xvivo Perfusion AB EV-to-OCF Related Terms
Xvivo Perfusion AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's EV-to-OCF falls into.
Xvivo Perfusion AB's current Enterprise Value is $807.68 Mil.
Xvivo Perfusion AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a EV-to-OCF of 41.45 as of Jun. 26, 2026. This is 65% below median its historical median of 116.77. According to the industry distribution chart, Xvivo Perfusion AB ranks #767 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 89.6%.
Is Xvivo Perfusion AB's EV-to-OCF too high?
Xvivo Perfusion AB's current EV-to-OCF of 41.45 is 65% below median its 10-year median of 116.77. The Medical Devices & Instruments industry median EV-to-OCF is 7.60. Xvivo Perfusion AB's value of 41.45 is 445.8% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #767 out of 856 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #767 out of 856 companies for EV-to-OCF. This places Xvivo Perfusion AB in the lower half of its industry. The industry median EV-to-OCF is 7.60. Xvivo Perfusion AB's value of 41.45 is 445.8% above this benchmark. While the company's 10-year median is 116.77 vs. the industry median of 7.60, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EV-to-OCF of 41.45 is 445.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EV-to-OCF is 41.45, which is 65% below median its own 10-year median of 116.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current EV-to-OCF is 41.45, which is 65% below median its 10-year median of 116.77 and 445.8% above the Medical Devices & Instruments industry median of 7.60. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current EV-to-OCF is 41.45 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
EV-to-OCF: 41.45 (65% below median its 10-year median of 116.77)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 445.8% above the Medical Devices & Instruments median (#767 of 856)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
